Review summary
Teaching objective: Evaluate chronic abdominal pain, diarrhea, and weight loss in a young woman of 21: confirm Crohn disease by ileocolonoscopy with biopsies and MR enterography, and exclude intestinal tuberculosis before any immunosuppression (interferon-gamma release assay, chest X-ray, and biopsies for acid-fast bacilli, TB PCR, and culture); classify the disease (Montreal) and its risk; start an advanced therapy early for moderate to severe disease, with latent tuberculosis, hepatitis B, and vaccine preparation first; correct iron, vitamin D, and nutrition; protect bone; treat to target with CRP, fecal calprotectin, and endoscopy; plan contraception, fertility, and pregnancy; screen mood; and help her keep composing. The historical illness is graded R: called intestinal tuberculosis in her time and proposed to be Crohn disease since, it is not settled.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| August 21, 1893 | Born in Paris. | CLM-0001, CLM-0002 |
| 1895 | Pneumonia at about two years old; frail health thereafter. | CLM-0003, CLM-0004 |
| 1913 | First woman to win the Premier Grand Prix de Rome for composition, with Faust et Hélène. | CLM-0005 |
| 1914 | Villa Medici in Rome; left for Nice when war broke out. | CLM-0006 |
| Early 1915 | In Paris: headaches, loss of appetite, fever, and colitis-like symptoms; much of the time in bed, still composing. | CLM-0007 |
| Late 1915 | With her sister, helped found the Franco-American Committee of the Conservatoire. | CLM-0008 |
| 1916 | Second stay in Rome, then return to France. | CLM-0006 |
| July 1917 | Operation in Paris; later dictated her music to her sister. | CLM-0011 |
| March 15, 1918 | Died at Mézy-sur-Seine; her illness described as intestinal tuberculosis and later proposed to be Crohn disease. | CLM-0012, CLM-0009, CLM-0010 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Lili Boulanger was born Marie-Juliette Olga Boulanger on August 21, 1893, in the 9th arrondissement of Paris. Reference works give the given names in different orders (Juliette Marie Olga; Julie-Marie Olga); the national library's civil-register form is used. |
confirmed | Boulanger, Lili (1893-1918): authority record supports Boulanger, Lili (1893–1918). Women in World History: A Biographical Encyclopedia supports Boulanger, Lili context |
| D | She was a composer, the sister of the composer and teacher Nadia Boulanger (1887–1979). | confirmed | Boulanger, Lili (1893-1918): authority record supports |
| D | At about two years old, in 1895, she had pneumonia, described as bronchial pneumonia; her health was frail from a very young age and she remained sickly for the rest of her life. | confirmed | Holland-Barry A. Lili Boulanger (21 August 1893–15 March 1918) supports Boulanger, Lili supports Coduti CL. Who Was Lili Boulanger? The Story Behind Soir sur la Plaine supports Boulanger, Lili (1893–1918). Women in World History: A Biographical Encyclopedia supports |
| R | The usual account is that the childhood pneumonia left her immune system weakened, so that she never fully recovered. A biographical interpretation, not a documented immune diagnosis; no test of her immunity exists. |
possible | Holland-Barry A. Lili Boulanger (21 August 1893–15 March 1918) supports Ueda Y. Boulanger, Lili (based on Spycket J, À la recherche de Lili Boulanger, Fayard, 2004) context |
| D | In 1913, at 19, she became the first woman to win the Premier Grand Prix de Rome for musical composition, with the cantata Faust et Hélène; she had been the only woman among the five finalists that May. | confirmed | Boulanger, Lili (1893-1918): authority record supports Boulanger, Lili (1893–1918). Women in World History: A Biographical Encyclopedia supports Boulanger, Lili supports Holland-Barry A. Lili Boulanger (21 August 1893–15 March 1918) supports |
| D | She went to the Villa Medici in Rome in 1914. The outbreak of war made her leave Rome for Nice, where she composed the song cycle Clairières dans le ciel; she stayed in Rome again in 1916 and then returned to France. One source says she instead made an unauthorized return to Paris in the summer of 1914; the record does not rely on either detail. |
confirmed | Boulanger, Lili supports Ueda Y. Boulanger, Lili (based on Spycket J, À la recherche de Lili Boulanger, Fayard, 2004) supports Graham D. Lili Boulanger: in her tragically short life, she helped shape 20th-century music context |
| D | Early in 1915, living in Paris, she began to have headaches, loss of appetite, and fever, followed by symptoms resembling colitis and appendicitis; she spent much of her time in bed but kept composing. Reported in an encyclopedia article drawn from the Spycket biography, which was not read directly. The documented presentation that anchors the synthetic episode. |
probable | Ueda Y. Boulanger, Lili (based on Spycket J, À la recherche de Lili Boulanger, Fayard, 2004) supports |
| D | During the war she and her sister helped to found the Franco-American Committee of the Conservatoire, which kept mobilized students in touch with the Conservatoire. | confirmed | Ueda Y. Boulanger, Lili (based on Spycket J, À la recherche de Lili Boulanger, Fayard, 2004) supports |
| R | Her chronic intestinal illness has been described as intestinal tuberculosis, and several reference works give tuberculosis as the cause of her death. No test from her lifetime confirming tuberculosis is reported in the sources read; whether she had intestinal tuberculosis is not settled. |
disputed | Coduti CL. Who Was Lili Boulanger? The Story Behind Soir sur la Plaine supports Boulanger, Lili (1893–1918). Women in World History: A Biographical Encyclopedia supports Boulanger, Lili supports Holland-Barry A. Lili Boulanger (21 August 1893–15 March 1918) supports |
| R | Later writers have proposed that her chronic intestinal illness was Crohn disease, which was not described as a distinct disease until well after her death. A retrospective diagnosis in program notes, a music magazine, and an encyclopedia article; no peer-reviewed analysis was found. It conflicts with the tuberculosis account, and the cause of death is not settled. |
disputed | Holland-Barry A. Lili Boulanger (21 August 1893–15 March 1918) supports Graham D. Lili Boulanger: in her tragically short life, she helped shape 20th-century music supports Ueda Y. Boulanger, Lili (based on Spycket J, À la recherche de Lili Boulanger, Fayard, 2004) supports Coduti CL. Who Was Lili Boulanger? The Story Behind Soir sur la Plaine supports |
| D | After her return to Paris in 1917 she had an operation at the end of July; the operation and its findings are not named in the source read. In her last illness, unable to hold a pen, she dictated her music to her sister. Later than the synthetic episode and not used in it. |
probable | Ueda Y. Boulanger, Lili (based on Spycket J, À la recherche de Lili Boulanger, Fayard, 2004) supports Graham D. Lili Boulanger: in her tragically short life, she helped shape 20th-century music supports |
| D | She died on March 15, 1918, at Mézy-sur-Seine (Yvelines), at 24. One reference biography places the death in Paris and another in the Paris area; the national library authority record gives Mézy-sur-Seine. Record the death as a fact without detail. |
confirmed | Boulanger, Lili (1893-1918): authority record supports Ueda Y. Boulanger, Lili (based on Spycket J, À la recherche de Lili Boulanger, Fayard, 2004) supports Boulanger, Lili (1893–1918). Women in World History: A Biographical Encyclopedia disputes Boulanger, Lili context |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Crohn disease of the terminal ileum and colon (ileocolitis), Montreal A2 L3 B1 without perianal disease, moderate to severe: deep ileal ulcers over 15 cm and patchy colonic ulcers, SES-CD 14, Harvey-Bradshaw Index 11; intestinal tuberculosis excluded by negative interferon-gamma release assay, normal chest X-ray, and biopsies negative for acid-fast bacilli, TB PCR, and mycobacterial culture; synthetic modern diagnosis linked to her documented chronic intestinal illness, whose historical diagnosis is not settled | active | confirmed | both_with_link | CLM-0007, CLM-0009, CLM-0010 |
| S | Four months of crampy right lower abdominal pain, loose stools up to six times a day including at night, low-grade evening fevers, and loss of 6 kg; inflammatory markers raised; colonoscopy and small-bowel imaging booked | resolved | confirmed | active | CLM-0007 |
| S | Iron deficiency anemia from chronic intestinal blood loss and poor absorption (hemoglobin 10.6 g/dL, MCV 76, ferritin 9) | resolved | confirmed | active | |
| S | Moderate protein-calorie malnutrition: BMI 17.6 after losing 6 kg (12 percent of body weight) in four months; albumin 3.3 g/dL | resolved | confirmed | active | |
| S | Vitamin D deficiency (25-hydroxyvitamin D 18 ng/mL) | resolved | confirmed | active | |
| S | Long-term use of risankizumab, an immunosuppressive biologic, for Crohn disease | active | confirmed | active | |
| S | Acute norovirus gastroenteritis on risankizumab, with mild dehydration; distinguished from a Crohn flare by the sudden onset, household contacts, and a positive stool PCR; resolved in three days | resolved | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 1915-01-19 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 2 | http://loinc.org · 55758-7 |
| S | 1915-01-19 | Hemoglobin [Mass/volume] in Blood | 10.6 g/dL (low) Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1915-01-19 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 76 fL (low) Reference 80-100 fL |
http://loinc.org · 787-2 |
| S | 1915-01-19 | Leukocytes [#/volume] in Blood by Automated count | 9.8 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1915-01-19 | Platelets [#/volume] in Blood by Automated count | 452 10*3/uL (high) Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1915-01-19 | C reactive protein [Mass/volume] in Serum or Plasma | 38 mg/L (high) Reference <=5 mg/L |
http://loinc.org · 1988-5 |
| S | 1915-01-19 | Calprotectin [Mass/mass] in Stool | 1240 ug/g (high) Reference <=50 ug/g |
http://loinc.org · 38445-3 |
| S | 1915-01-19 | Albumin [Mass/volume] in Serum or Plasma | 3.3 g/dL (low) Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 1915-01-19 | Ferritin [Mass/volume] in Serum or Plasma | 9 ng/mL (low) Reference 15-150 ng/mL |
http://loinc.org · 2276-4 |
| S | 1915-01-19 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 310 pg/mL Reference 200-900 pg/mL |
http://loinc.org · 2132-9 |
| S | 1915-01-19 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 18 ng/mL (low) Reference 30-100 ng/mL |
http://loinc.org · 62292-8 |
| S | 1915-01-19 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 16 U/L Reference <=33 U/L |
http://loinc.org · 1742-6 |
| S | 1915-01-19 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 U/L Reference <=32 U/L |
http://loinc.org · 1920-8 |
| S | 1915-01-19 | Creatinine [Mass/volume] in Serum or Plasma | 0.7 mg/dL Reference 0.5-1.1 mg/dL |
http://loinc.org · 2160-0 |
| S | 1915-01-28 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | http://loinc.org · 44261-6 |
| S | 1915-01-28 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 9 | http://loinc.org · 70274-6 |
| S | 1915-01-28 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 U/L Reference <=33 U/L |
http://loinc.org · 1742-6 |
| S | 1915-01-28 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 U/L Reference <=32 U/L |
http://loinc.org · 1920-8 |
| S | 1915-01-28 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.4 mg/dL Reference <=1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 1915-01-28 | DXA Lumbar spine [Z-score] Bone density | -1.4 Reference A Z-score of -2.0 or below is below the expected range for age |
http://loinc.org · 85394-5 |
| S | 1915-01-28 | DXA Femur [Z-score] Bone density | -1.1 Reference A Z-score of -2.0 or below is below the expected range for age |
http://loinc.org · 80934-3 |
| S | 1915-03-02 | Hemoglobin [Mass/volume] in Blood | 11.6 g/dL (low) Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1915-03-02 | C reactive protein [Mass/volume] in Serum or Plasma | 8 mg/L (high) Reference <=5 mg/L |
http://loinc.org · 1988-5 |
| S | 1915-03-02 | Albumin [Mass/volume] in Serum or Plasma | 3.7 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 1915-03-02 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 U/L Reference <=33 U/L |
http://loinc.org · 1742-6 |
| S | 1915-03-02 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 U/L Reference <=32 U/L |
http://loinc.org · 1920-8 |
| S | 1915-03-02 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 mg/dL Reference <=1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 1915-03-02 | Phosphate [Mass/volume] in Serum or Plasma | 3 mg/dL Reference 2.5-4.5 mg/dL |
http://loinc.org · 2777-1 |
| S | 1915-03-02 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | http://loinc.org · 44261-6 |
| S | 1915-03-02 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | http://loinc.org · 70274-6 |
| S | 1915-04-27 | Hemoglobin [Mass/volume] in Blood | 12.6 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1915-04-27 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 83 fL Reference 80-100 fL |
http://loinc.org · 787-2 |
| S | 1915-04-27 | Ferritin [Mass/volume] in Serum or Plasma | 86 ng/mL Reference 15-150 ng/mL |
http://loinc.org · 2276-4 |
| S | 1915-04-27 | C reactive protein [Mass/volume] in Serum or Plasma | 3 mg/L Reference <=5 mg/L |
http://loinc.org · 1988-5 |
| S | 1915-04-27 | Calprotectin [Mass/mass] in Stool | 210 ug/g (high) Reference <=50 ug/g |
http://loinc.org · 38445-3 |
| S | 1915-04-27 | Albumin [Mass/volume] in Serum or Plasma | 4.1 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 1915-04-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 U/L Reference <=33 U/L |
http://loinc.org · 1742-6 |
| S | 1915-04-27 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 U/L Reference <=32 U/L |
http://loinc.org · 1920-8 |
| S | 1915-04-27 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 mg/dL Reference <=1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 1915-04-27 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 ng/mL Reference 30-100 ng/mL |
http://loinc.org · 62292-8 |
| S | 1915-08-03 | Hemoglobin [Mass/volume] in Blood | 13.1 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1915-08-03 | Ferritin [Mass/volume] in Serum or Plasma | 72 ng/mL Reference 15-150 ng/mL |
http://loinc.org · 2276-4 |
| S | 1915-08-03 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 340 pg/mL Reference 200-900 pg/mL |
http://loinc.org · 2132-9 |
| S | 1915-08-03 | C reactive protein [Mass/volume] in Serum or Plasma | 2 mg/L Reference <=5 mg/L |
http://loinc.org · 1988-5 |
| S | 1915-08-03 | Calprotectin [Mass/mass] in Stool | 42 ug/g Reference <=50 ug/g |
http://loinc.org · 38445-3 |
| S | 1915-08-03 | Albumin [Mass/volume] in Serum or Plasma | 4.3 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 1915-08-03 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | http://loinc.org · 44261-6 |
| S | 1915-04-13 | Leukocytes [#/volume] in Blood by Automated count | 9.4 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1915-04-13 | C reactive protein [Mass/volume] in Serum or Plasma | 11 mg/L (high) Reference <=5 mg/L |
http://loinc.org · 1988-5 |
| S | 1915-04-13 | Potassium [Moles/volume] in Serum or Plasma | 3.4 mmol/L (low) Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1915-04-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 mg/dL Reference 0.5-1.1 mg/dL |
http://loinc.org · 2160-0 |
| S | 1915-04-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 U/L Reference <=33 U/L |
http://loinc.org · 1742-6 |
| S | 1915-10-19 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 1915-10-19 | Total score [AUDIT-C] | 0 | http://loinc.org · 75626-2 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 1915-01-19 | Body height | 160 cm | 8302-2 | S |
| 1915-01-19 | Body weight | 45 kg | 29463-7 | S |
| 1915-01-19 | Body mass index (BMI) [Ratio] | 17.6 kg/m2 | 39156-5 | S |
| 1915-01-19 | Systolic blood pressure | 104 mm[Hg] | 8480-6 | S |
| 1915-01-19 | Diastolic blood pressure | 66 mm[Hg] | 8462-4 | S |
| 1915-01-19 | Heart rate | 96 /min | 8867-4 | S |
| 1915-01-19 | Respiratory rate | 16 /min | 9279-1 | S |
| 1915-01-19 | Body temperature | 37.6 Cel | 8310-5 | S |
| 1915-01-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1915-01-28 | Body height | 160 cm | 8302-2 | S |
| 1915-01-28 | Body weight | 44.8 kg | 29463-7 | S |
| 1915-01-28 | Body mass index (BMI) [Ratio] | 17.5 kg/m2 | 39156-5 | S |
| 1915-01-28 | Systolic blood pressure | 102 mm[Hg] | 8480-6 | S |
| 1915-01-28 | Diastolic blood pressure | 64 mm[Hg] | 8462-4 | S |
| 1915-01-28 | Heart rate | 92 /min | 8867-4 | S |
| 1915-01-28 | Respiratory rate | 16 /min | 9279-1 | S |
| 1915-01-28 | Body temperature | 37.4 Cel | 8310-5 | S |
| 1915-01-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1915-03-02 | Body height | 160 cm | 8302-2 | S |
| 1915-03-02 | Body weight | 46.4 kg | 29463-7 | S |
| 1915-03-02 | Body mass index (BMI) [Ratio] | 18.1 kg/m2 | 39156-5 | S |
| 1915-03-02 | Systolic blood pressure | 108 mm[Hg] | 8480-6 | S |
| 1915-03-02 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 1915-03-02 | Heart rate | 84 /min | 8867-4 | S |
| 1915-03-02 | Respiratory rate | 14 /min | 9279-1 | S |
| 1915-03-02 | Body temperature | 36.8 Cel | 8310-5 | S |
| 1915-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1915-04-27 | Body height | 160 cm | 8302-2 | S |
| 1915-04-27 | Body weight | 48.4 kg | 29463-7 | S |
| 1915-04-27 | Body mass index (BMI) [Ratio] | 18.9 kg/m2 | 39156-5 | S |
| 1915-04-27 | Systolic blood pressure | 106 mm[Hg] | 8480-6 | S |
| 1915-04-27 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 1915-04-27 | Heart rate | 76 /min | 8867-4 | S |
| 1915-04-27 | Respiratory rate | 14 /min | 9279-1 | S |
| 1915-04-27 | Body temperature | 36.7 Cel | 8310-5 | S |
| 1915-04-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1915-08-03 | Body height | 160 cm | 8302-2 | S |
| 1915-08-03 | Body weight | 50.6 kg | 29463-7 | S |
| 1915-08-03 | Body mass index (BMI) [Ratio] | 19.8 kg/m2 | 39156-5 | S |
| 1915-08-03 | Systolic blood pressure | 108 mm[Hg] | 8480-6 | S |
| 1915-08-03 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 1915-08-03 | Heart rate | 72 /min | 8867-4 | S |
| 1915-08-03 | Respiratory rate | 14 /min | 9279-1 | S |
| 1915-08-03 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1915-08-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1915-04-13 | Body height | 160 cm | 8302-2 | S |
| 1915-04-13 | Body weight | 46.9 kg | 29463-7 | S |
| 1915-04-13 | Body mass index (BMI) [Ratio] | 18.3 kg/m2 | 39156-5 | S |
| 1915-04-13 | Systolic blood pressure | 98 mm[Hg] | 8480-6 | S |
| 1915-04-13 | Diastolic blood pressure | 62 mm[Hg] | 8462-4 | S |
| 1915-04-13 | Heart rate | 98 /min | 8867-4 | S |
| 1915-04-13 | Respiratory rate | 16 /min | 9279-1 | S |
| 1915-04-13 | Body temperature | 37.7 Cel | 8310-5 | S |
| 1915-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1915-10-19 | Body height | 160 cm | 8302-2 | S |
| 1915-10-19 | Body weight | 51.4 kg | 29463-7 | S |
| 1915-10-19 | Body mass index (BMI) [Ratio] | 20.1 kg/m2 | 39156-5 | S |
| 1915-10-19 | Systolic blood pressure | 108 mm[Hg] | 8480-6 | S |
| 1915-10-19 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 1915-10-19 | Heart rate | 70 /min | 8867-4 | S |
| 1915-10-19 | Respiratory rate | 14 /min | 9279-1 | S |
| 1915-10-19 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1915-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Occupation: composer, prize-winning; composes at the piano most days and is preparing a concert of her choral works for March
- S Never smoker; no alcohol; eats small meals because food brings on cramps
- S Lives in a shared apartment in the city; independent
- S Supports: close friends and fellow musicians; her teachers at the conservatory
- S Reproductive and sexual health: menarche at 13; periods irregular since the weight loss; no pregnancies; not sexually active at present; would like children someday but not in the next few years
Functional status
- S Independent; tires easily and spends much of the afternoon resting; plans her day around access to a bathroom; still composes in the mornings
Mental status
- S Alert, articulate, and determined; worried that illness will cost her the concert
- S Mood low at times with the illness; PHQ-2 score 2
Allergies and medications
Allergies
- S No known allergy
Medications
- S Acetaminophen 500 mg oral tablet, one or two tablets by mouth up to every 6 hours as needed for abdominal pain, no more than 3000 mg a day; no nonsteroidal anti-inflammatory drugs
- S Prednisone 20 mg oral tablet: 40 mg by mouth each morning, reduced by 5 mg each week over eight weeks, as a bridge until risankizumab takes effect
- S Risankizumab 600 mg in 10 mL intravenous infusion over at least one hour at weeks 0, 4, and 8 (induction)
- S Risankizumab 360 mg in 2.4 mL by subcutaneous on-body injector every 8 weeks (maintenance), from week 12
- S Ferric derisomaltose 1000 mg in 10 mL intravenous infusion, single dose
- S Cholecalciferol (vitamin D3) 1889 units oral tablet, one tablet by mouth once daily
- S Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet by mouth once daily with food while on prednisone
Procedures and immunizations
Procedures
- S Chest X-ray before possible immunosuppression and to look for tuberculosis: normal lungs, no hilar nodes, no calcified granulomas
- S Ileocolonoscopy with biopsies: deep longitudinal ulcers over the last 15 cm of the terminal ileum; patchy aphthous and serpiginous ulcers in the ascending and transverse colon with normal mucosa between; rectum spared; ileocecal valve patulous, not stenosed; SES-CD 14. Biopsies: chronic active ileitis and colitis with crypt architectural distortion and a few small non-caseating granulomas; acid-fast stain negative, TB PCR (Xpert MTB/RIF) negative; mycobacterial culture sent
- S MR enterography: 18 cm of terminal ileal wall thickening (7 mm) with mucosal hyperenhancement and the comb sign; no stricture with upstream dilation, no fistula, abscess, or necrotic lymph nodes; no ascites; ascending colon wall thickening
- S Baseline bone density scan (DXA): lumbar spine Z-score -1.4, femoral neck Z-score -1.1, within the expected range for age
- S Follow-up ileocolonoscopy eight months into risankizumab: healed ileal ulcers with a few small aphthae and scarring; colon healed; SES-CD 2 (endoscopic response, near remission); no stricture
Immunizations
- S 1914-10-20: Influenza vaccine, 1914-1915 season
- S 1905-09-12: Tdap vaccine
- S 1915-01-28: Pneumococcal conjugate vaccine PCV20, before immunosuppression
- S 1915-01-28: Recombinant zoster vaccine, dose 1 of 2, before immunosuppression
- S 1915-01-28: Hepatitis B vaccine, adult booster dose (infant series, anti-HBs below 10 mIU/mL)
- S 1915-04-27: Recombinant zoster vaccine, dose 2 of 2
- S 1915-10-19: Influenza vaccine, 1915-1916 season
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 1895: Pneumonia at about two years old, described as bronchial pneumonia, with frail health afterwards (CLM-0003)
- D Early 1915: Headaches, loss of appetite, fever, and symptoms resembling colitis and appendicitis, with much time in bed (CLM-0007)
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Reach a diagnosis, with tuberculosis excluded, within two weeks | 1915-01-28 | completed | Ileocolonoscopy, biopsies, MR enterography, interferon-gamma release assay, and chest X-ray completed in nine days; Crohn disease diagnosed and intestinal tuberculosis made very unlikely, with the mycobacterial culture still pending |
| Steroid-free clinical remission by week 12 to 16 of treatment | 1915-04-27 | completed | Harvey-Bradshaw Index 2 at week 12, five weeks after the prednisone taper ended |
| Normal CRP and fecal calprotectin by six months, and endoscopic response at six to twelve months | 1915-10-05 | completed | CRP 2 mg/L and calprotectin 42 ug/g at six months; SES-CD 14 to 2 at eight months |
| Regain weight to a BMI of 19 or more and correct iron and vitamin D | 1915-08-03 | completed | Weight 50.6 kg (BMI 19.8); hemoglobin 13.1, ferritin 72, vitamin D 34 |
| Perform her March concert and keep composing through treatment | 1915-04-27 | completed | Composing most mornings; the concert went ahead in late March with a plan for bathroom access |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Workup for suspected inflammatory bowel disease: blood count, CRP, albumin, iron studies, vitamin B12 and D, fecal calprotectin, stool tests for Clostridioides difficile and enteric pathogens, celiac serology, a pregnancy test, ileocolonoscopy with biopsies, and MR enterography | completed | GL-ACG-CD-2025, GL-ECCO-ESGAR-2019 |
| Exclude intestinal tuberculosis before any steroid or immunosuppressive drug: interferon-gamma release assay, chest X-ray, and ileal and colonic biopsies for acid-fast stain, TB PCR, and mycobacterial culture; with hepatitis B, hepatitis C, HIV, measles, and varicella serology before treatment | completed | GL-ECCO-INF-2026, GL-ACG-CD-2025 |
| Gastroenterology (inflammatory bowel disease) consultation once the endoscopy and imaging are done, to confirm the diagnosis and choose treatment with her | completed | GL-ACG-CD-2025, GL-AGA-CD-2021 |
| Nutrition: dietitian assessment, small frequent meals with oral nutritional supplements, and weight at every visit | completed | GL-ECCO-CD-2024, GL-ACG-PREV-2025 |
| Mood, anxiety, and work: PHQ-9 and GAD-7 at intervals, IBD psychology if needed, and a practical plan for composing and performing during treatment | completed | GL-ACG-PREV-2025 |
| Risankizumab 600 mg intravenously at weeks 0, 4, and 8, then 360 mg subcutaneously every 8 weeks, chosen with her as early advanced therapy; liver enzymes and bilirubin at baseline and through at least week 12; a short prednisone bridge tapered over eight weeks; no live vaccines | completed | GL-ACG-CD-2025, GL-AGA-CD-2021, GL-ECCO-CD-2024, GL-FDA-RISANKIZUMAB-2026 |
| Vaccines before immunosuppression: PCV20, recombinant zoster vaccine in two doses, a hepatitis B booster with an antibody check one to two months later, and influenza and COVID-19 vaccines each season; live vaccines not needed because she is immune to measles and varicella | completed | GL-ACG-PREV-2025, GL-CDC-IMZ-2026, GL-ECCO-INF-2026 |
| Iron, vitamin D, and bone: one intravenous ferric derisomaltose infusion, vitamin D3 daily, calcium while on prednisone, baseline DXA, and weight-bearing exercise | completed | GL-ACG-PREV-2025, GL-ECCO-CD-2024 |
| Treat to target: symptoms and CRP at every visit, fecal calprotectin at about three and six months, and ileocolonoscopy at six to twelve months | completed | GL-STRIDE-2021, GL-ACG-CD-2025 |
| Contraception, fertility, and pregnancy planning: effective contraception while the disease is active; plan pregnancy after three to six months of steroid-free remission, with a preconception review; continue the biologic in pregnancy after discussing the limited data for risankizumab; folic acid before conception | completed | GL-PREG-IBD-2025, GL-FDA-RISANKIZUMAB-2026 |
Planned encounters
- 1915-01-19 — Primary care visit for four months of abdominal pain, diarrhea, fevers, and weight loss (ENC-001)
- 1915-01-28 — Diagnosis of Crohn disease with intestinal tuberculosis excluded; inflammatory bowel disease consultation the same day (ENC-002)
- 1915-03-02 — Review at week 4 of risankizumab, on the day of the second induction infusion (ENC-003)
- 1915-04-13 — Same-day sick visit for vomiting and diarrhea on risankizumab (ENC-006, unscheduled)
- 1915-04-27 — Review at week 12, the first maintenance dose of risankizumab (ENC-004)
- 1915-08-03 — Six-month review on maintenance risankizumab (ENC-005)
- 1915-10-19 — Adult preventive visit (ENC-007)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Sick Visit
- Progress note 05 — Focused Visit (Follow-up)
- Progress note 06 — Focused Visit (Care-plan review)
- Progress note 07 — Preventive Visit
- Gastroenterology (inflammatory bowel disease) referral
- Gastroenterology (inflammatory bowel disease) consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Sick Visit (XML)
- Progress note 05 — Focused Visit (Follow-up) (XML)
- Progress note 06 — Focused Visit (Care-plan review) (XML)
- Progress note 07 — Preventive Visit (XML)
- Gastroenterology (inflammatory bowel disease) referral (XML)
- Gastroenterology (inflammatory bowel disease) consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Boulanger, Lili (1893-1918): authority record | Bibliothèque nationale de France | government |
| SRC-0002 | Boulanger, Lili (1893–1918). Women in World History: A Biographical Encyclopedia | Encyclopedia.com (Gale) | biography |
| SRC-0003 | Boulanger, Lili | Bru Zane Mediabase (Palazzetto Bru Zane, Centre de musique romantique française) | biography |
| SRC-0004 | Holland-Barry A. Lili Boulanger (21 August 1893–15 March 1918) | RISM (Répertoire International des Sources Musicales) | biography |
| SRC-0005 | Ueda Y. Boulanger, Lili (based on Spycket J, À la recherche de Lili Boulanger, Fayard, 2004) | PTNA Piano Encyclopedia | biography |
| SRC-0006 | Coduti CL. Who Was Lili Boulanger? The Story Behind Soir sur la Plaine | Pacific Chorale | other |
| SRC-0007 | Graham D. Lili Boulanger: in her tragically short life, she helped shape 20th-century music | BBC Music Magazine (classical-music.com) | other |
| SRC-0008 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the exclusion of intestinal tuberculosis, the choice of risankizumab over an anti-TNF with an immunomodulator, the prednisone bridge, the vaccine plan, and the pregnancy counseling. |
| provenance review | not_started | Dates, names, and the Prix de Rome from the Bibliothèque nationale de France authority record and reference biographies; the early-1915 symptoms from an encyclopedia article drawn from the Spycket biography; the intestinal tuberculosis and Crohn disease accounts graded R and disputed. Grove and the Fauser and Spycket works were not read directly. Her sister and mother appear only in documented claims. |
| safe messaging review | not_started | No behavioral-health diagnosis; mild distress at diagnosis is screened and supported; death recorded without detail. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.